Back to Authors

Boyer, Suzanne W

Mayo Clinic

Department of Clinical Genomics Mayo Clinic Rochester Minnesota USA.

Citations 2

PIGO‐CDG: A case study with a new genotype, expansion of the phenotype, literature review, and nosological considerations
Starosta, Rodrigo Tzovenos , Kerashvili, Nino, Pruitt, Cassandra, Boyer, Suzanne, Lasio, Maria Laura Duque , Grange, Dorothy K. , Boyer, Suzanne W, Grange, Dorothy K , Schultz, Matthew , Morava, Éva

JIMD Reports | September 21, 2023 | Volume: 64 | Issue: 6 | Pages: 424-433

10.1002/jmd2.12396 Get It

AbstractThe phosphatidylinositol glycan anchor biosynthesis class O protein (PIGO) enzyme is an important step in the biosynthesis of glycosylphosphatidylinositol (GPI), which is essential for the membrane anchoring of several proteins. Bi‐allelic pathogenic variants in PIGO lead to a congenital disorder of glycosylation (CDG) characterized by global developmental delay, an increase in serum alkaline phosphatase levels, congenital anomalies including anorectal, genitourinary, and limb malformations in most patients; this phenotype has been alternately called “Mabry syndrome” or “hyperphosphatasia with impaired intellectual development syndrome 2.” We report a 22‐month‐old female with PIGO deficiency caused by novel PIGO variants. In addition to the Mabry syndrome phenotype, our patient's clinical picture was complicated by intermittent hypoglycemia with signs of functional hyperinsulinism, severe secretory diarrhea, and osteopenia with a pathological fracture, thus, potentially expanding the known phenotype of this disorder, although more studies are necessary to confirm these associations. We also provide an updated review of the literature, and propose unifying the nomenclature of PIGO deficiency as “PIGO‐CDG,” which reflects its pathophysiology and position in the broad scope of metabolic disorders and congenital disorders of glycosylation.
PMM2‐CDG caused by uniparental disomy: Case report and literature review
Vaes, Laurien, Tiller, George E. , Boyer, Suzanne, Berry, Susan A. , Sarafoglou, Kyriakie , Morava, Éva , Boyer, Suzanne W, Morava, Eva , Boyer, Suzanne , Pérez, Belén

JIMD Reports | April 28, 2020 | Volume: 54 | Issue: 1 | Pages: 16-21

10.1002/jmd2.12122 Get It

AbstractBackgroundPhosphomannomutase 2 deficiency (PMM2‐CDG) affects glycosylation pathways such as the N‐glycosylation pathway, resulting in loss of function of multiple proteins. This disorder causes multisystem involvement with a high variability among patients. PMM2‐CDG is an autosomal recessive disorder, which can be caused by inheriting two pathogenic variants, de novo mutations or uniparental disomy.Case PresentationOur patient presented with multisystem symptoms at an early age including developmental delay, ataxia, and seizures. No diagnosis was obtained till the age of 31 years, when genetic testing was reinitiated. The patient was diagnosed with a complete maternal mixed hetero/isodisomy of chromosome 16, with a homozygous pathogenic PMM2 variant (p.Phe119Leu) causing PMM2‐CDG.A literature review revealed eight cases of uniparental disomy as an underlying cause of CDG, four of which are PMM2‐CDG.ConclusionSince the incidence of homozygosity for PMM2 variants is rare, we suggest further investigations for every homozygous PMM2‐CDG patient where the segregation does not fit. These investigations include testing for UPD or a deletion in one of the two alleles, as this will have an impact on recurrence risk in genetic counseling.